Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice

Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice

Relevance. Data on the efficacy of endocrine and chemotherapy regimens in patients with hormone-resistant metastatic breast cancer (mBC) after progression with CDK4/6 inhibitors are limited; the search for an effective therapy regimen in this clinical situation is an urgent task of clinical oncology...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Irina V. Kolyadina, Natalia R. Abidova, Arshak A. Akopyan, Galina V. Antonova, Oksana I. Arapova, Elvira A. Bobrova, Larisa V. Bolotina, Chulpan K. Valiakhmetova, Anna V. Vasilevskaya, Lyubov Y. Vladimirova, Mikhail V. Volkonskiy, Inna P. Ganshina, Irina E. Gudkova, Alexandr S. Dergunov, Irina V. Evstigneeva, Viktoria S. Egurenkova, Aleksei V. Emshanov, Lyudmila G. Zhukova, Elena V. Zueva, Elena V. Karabina, James J. Kolokolov, Svetlana V. Kuzmicheva, Olesya A. Kuchevskaya, Ivan A. Luev, Ksenia S. Maistrenko, Elena V. Markizova, Vasily V. Marfutov, Sergey P. Medvedev, Yulia I. Merzlikina, Tatyana A. Nersesova, Elena G. Ovchinnikova, Svetlana A. Orlova, Natalia Y. Samaneva, Olesya A. Stativko, Anna E. Storozhakova, Daniil L. Stroyakovskiy, Alexander V. Sultanbaev, Asiat I. Tekeeva, Natalia V. Fadeeva, Alina N. Fedorova, Oksana M. Shalaeva, Irina A. Shangina, Oksana N. Shirokova, Alisa R. Shumskikh, Mariam Z. Yakubova
Formato: article
Lenguaje:RU
Publicado: IP Habib O.N. 2021
Materias:
hr+/her2- metastatic breast cancer
cdk4/6
combined endocrine therapy with cdk4/6 inhibitors
hormone resistance
eribulin
eribulin chemotherapy efficacy
eribulin chemotherapy safety
visceral metastases
lung metastases
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/714a7172db8b443795259379d343327b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/714a7172db8b443795259379d343327b

Ejemplares similares